EUSA Pharma
Founded in 2006, EUSA Pharma is a global specialty pharmaceutical company headquartered in the UK. It focuses on oncology and critical diseases, offering a portfolio of approved products such as Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. The company aims to expand its portfolio through acquisitions and strategic partnerships, supported by significant funding from Essex Woodlands.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Cytogen Corporation
Acquisition in 2008
Cytogen is a biopharmaceutical company that is focused on the development and building of pharmaceutical products for cancer patients.
Cytogen markets QUADRAMET, PROSTASCINT, CAPHOSOL, and SOLTAMOX. It also develops CYT-500, a third-generation radiolabeled antibody to treat prostate cancer.
Cytogen was acquired by EUSA Pharma in May 2008.
Cytogen was founded by Thomas J. McKearn in 1980. It is based in Princeton, New Jersey.
Talisker Pharma
Acquisition in 2006
Sale marketing and distribution of pharmaceutical products
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.